Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02671526 · ClinicalTrials.gov registry record · NA
Cognitive Remediation for HIV-associated Neurocognitive Dysfunction
A NA study, sponsored by Posit Science Corporation.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT02671526: Completed NA study, sponsored by Posit Science Corporation.
NCT02671526 is a NA study that has completed, run by Posit Science Corporation. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02671526, a NA study, has completed, sponsored by Posit Science Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study is a validation study to document the acceptability of the revised Plasticity-based Adaptive Cognitive Remediation (PACR) program to patients with HIV-associated Neurocognitive Dysfunction (HAND). The primary objective of this study is to evaluate the effects of the revised PACR program on the cognitive abilities (e.g., attention, executive function), functional status and quality of life of individuals diagnosed with HAND. The secondary objective of the study is to collect relevant data to support a pre-investigational device exemption (IDE) submission to the FDA required before the pivotal randomized, controlled trial planned for Phase II.
Primary Outcome
The primary outcome measure is the useful field of view; change on this measure suggests underlying neural change, and has been shown to predict overall cognitive change. The exercise-based measure serves as a positive control for task learning. The investigators anticipate improvements in this assessment because participants have directly practiced these tasks, as well as tasks within related cognitive domains. The data are relevant because individuals failing to make progress on this assessmen
Interventions
- OTHER Computerized plasticity-based adaptive cognitive training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-11 |
| Phase | NA |
What the finished NCT02671526 record still lists
NCT02671526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Computerized plasticity-based adaptive cognitive training is the first listed.
NCT02671526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02671526 about?
NCT02671526 is a clinical study titled "Cognitive Remediation for HIV-associated Neurocognitive Dysfunction". This study is a validation study to document the acceptability of the revised Plasticity-based Adaptive Cognitive Remediation (PACR) program to patients with HIV-associated Neurocognitive Dysfunction (HAND). The primary objective of this study is to evaluate the effects of the revised PACR program o...
What is the current status of trial NCT02671526?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2015-12. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02671526?
The interventions under investigation include: Computerized plasticity-based adaptive cognitive training (OTHER).
Who is sponsoring clinical trial NCT02671526?
This trial is sponsored by Posit Science Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02671526's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia